NRIX
Nurix Therapeutics Inc
23.00$
-1.5%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Cash Flow
Nurix Therapeutics Inc (NRIX) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -97 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -9.7 | -13 | 36 | -13 | 41 | -14 | -6.1 | -20 | 8.1 | -32 | -30 | -31 | -43 | -33 | -46 | -38 | -48 | -18 | -41 | 27 | -42 | -40 | -42 | -49 | -61 | -63 | -57 | -68 | -72 | -97 | -294 | |
| 0.6 | 0.6 | 0.6 | 0.5 | 0.5 | 0.5 | 0.6 | 0.6 | 0.6 | 0.6 | 0.7 | 4.0 | 2.3 | 2.6 | 2.9 | 3.0 | 3.2 | 3.3 | 3.4 | 3.8 | 3.9 | 4.1 | 4.1 | 4.3 | 4.1 | 5.1 | 5.0 | 4.6 | 3.8 | 3.9 | 17 | |
| 0.1 | 0.1 | 0.1 | 0.2 | 0.2 | 0.5 | 1.1 | 2.5 | 2.7 | 3.9 | 4.3 | 4.8 | 6.1 | 6.8 | 7.0 | 8.3 | 8.5 | 8.7 | 8.4 | 8.0 | 7.8 | 8.8 | 8.8 | 8.5 | 8.7 | 10 | 9.8 | 9.1 | 9.4 | 11 | 40 | |
| 0.0 | 0.1 | 0.1 | – | 0.2 | 0.5 | 1.2 | 2.7 | 2.9 | 4.3 | 5.0 | 5.4 | 6.6 | 7.4 | 7.1 | 7.6 | 7.8 | 7.8 | 7.2 | – | – | – | – | – | – | – | – | – | – | – | – | |
| 0.6 | -0.3 | 38 | 0.1 | 53 | -23 | 11 | -3.9 | 29 | -10 | -6.9 | -2.7 | -9.0 | 2.4 | -11 | -1.9 | -19 | -5.3 | -15 | 54 | -10 | -5.9 | -2.7 | 0.4 | -14 | -32 | 16 | -1.6 | 3.9 | -3.9 | 15 | |
| 0.2 | 0.0 | 0.5 | 1.0 | 0.4 | 1.6 | 1.7 | 0.9 | 0.8 | 2.1 | 1.9 | 0.9 | 3.5 | 2.8 | 3.4 | 2.6 | 2.3 | 1.1 | 2.5 | 2.6 | 2.9 | 1.9 | 2.3 | 2.1 | 3.5 | 2.7 | 2.7 | 5.1 | 1.0 | 1.9 | 11 | |
| -0.6 | 10.0 | 3.5 | -4.4 | -19 | -2.3 | -108 | -125 | -2.4 | -57 | -12 | -37 | 40 | -4.8 | -63 | 55 | 16 | 44 | 23 | -14 | 36 | -131 | -21 | -141 | 26 | 71 | 50 | 0.3 | -124 | 93 | 20 | |
| 0.0 | 0.0 | 0.0 | – | 0.0 | 120 | – | – | 0.0 | 150 | 0.5 | 2.6 | – | – | – | – | – | – | – | – | – | 0.0 | 0.0 | – | – | 1.3 | 2.2 | – | 1.6 | – | – | |
| 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 120 | 220 | -1.1 | 1.4 | 150 | 1.6 | 0.5 | 1.5 | 0.4 | 115 | -0.1 | 1.5 | 0.0 | 1.7 | 0.0 | 1.6 | 238 | 46 | 201 | 1.5 | 0.0 | 1.2 | 236 | 20 | 0.1 | 257 | |
| -10 | -3.3 | 40 | -17 | 22 | 103 | 106 | -146 | 7.0 | 62 | -41 | -67 | -1.1 | -37 | 6.0 | 17 | -31 | 25 | -17 | 12 | -4.8 | 67 | -18 | 11 | -34 | 8.3 | -5.8 | 169 | -176 | -3.5 | -17 | |
| -9.8 | -13 | 36 | -14 | 41 | -16 | -7.8 | -21 | 7.2 | -34 | -32 | -32 | -46 | -36 | -50 | -41 | -51 | -20 | -44 | 24 | -45 | -42 | -45 | -51 | -65 | -66 | -60 | -73 | -73 | -99 | -305 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.